MOJ
eISSN: 2574-8130
Submit manuscript...
Review Article Volume 10 Issue 2
Impact of new biological, genetic, immunotherapies, monoclonal antibodies, car T cells and vaccines in the treatment of cancer in the elderly
Adrian Hunis MD, Melisa Hunis MD
School of Medicine, Universidad de Buenos Aires, Argentina
Received: July 23, 2025 | Published: July 30, 2025
Citation: Hunis M, Hunis A. Impact of new biological, genetic, immunotherapies, monoclonal antibodies, car T cells, and vaccines in the treatment of cancer in the elderly. MOJ Gerontol Ger. 2025;10(2):51‒55 DOI: 10.15406/mojgg.2025.10.00339
Abstract
The
demographic shift toward an aging population has led to a dramatic rise in
cancer incidence among older adults. Traditional cytotoxic chemotherapy
presents unique challenges in geriatric patients due to frailty, comorbidities,
and altered pharmacokinetics. In recent years, the advent of biological
therapies, genetic approaches, immunotherapies—including immune checkpoint
inhibitors—monoclonal antibodies, CAR T cell therapies, and therapeutic vaccines
has revolutionized cancer management. The most common malignancies affecting
the elderly include breast, lung, colorectal, and prostate cancers, which are
the primary focus of this review. These novel modalities offer the potential
for improved efficacy and a more favorable toxicity profile, but their
application in the elderly requires careful consideration of age-related
physiological changes, functional status, and geriatric syndromes. This review
provides a comprehensive analysis of the impact of these new treatments on
elderly cancer patients, discussing their mechanisms, indications in common
malignancies, clinical outcomes, toxicity profiles, and future directions for
geriatric oncology.
Keywords: older adults,landscape, novel cancer therapies,medical, functional, psychological, cancer therapies, geriatric assessment
©2025 Hunis, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.